$552.85
5.260.96%
At close: Aug 24, 5:00 PM EST
$554.78
7.191.31%
Pre-Market: 4:43 AM EST
Vertex Pharmaceuticals Inc Stock Guidance
VRTXNASDAQ
Vertex Pharmaceuticals (VRTX) last issued guidance on August 3, 2026 for fiscal year 2026. The company guided revenue in the range of $13.1B - $13.2B for the period.
Compared to prior guidance, Vertex Pharmaceuticals maintained its revenue forecast from a prior range of $12.95B - $13.1B.
Vertex Pharmaceuticals has issued 16 guidance updates between October 27, 2022 and August 3, 2026. During this period, the company raised its outlook 6 times, reflecting management's growing confidence in business performance.
Latest Guidance Date
Aug 3, 2026
Guidance Period
Full Year 2026
Revenue Guidance Range
$13.1B - $13.2B
Vertex Pharmaceuticals Guidance History
Review all historical guidance issued by Vertex Pharmaceuticals, including EPS and revenue forecasts across quarterly and annual periods.
FAQ
What is the most recent guidance for Vertex Pharmaceuticals (VRTX)?
The most recent guidance for Vertex Pharmaceuticals (VRTX) was reported on August 3, 2026 for the fiscal year 2026. Vertex Pharmaceuticals forecasted revenue between $13.1B and $13.2B for the period.
What revenue range did Vertex Pharmaceuticals (VRTX) guide for?
Vertex Pharmaceuticals (VRTX) guided revenue in the range of $13.1B to $13.2B for the fiscal year 2026.
Did Vertex Pharmaceuticals (VRTX) raise or lower guidance?
Vertex Pharmaceuticals (VRTX) maintained its revenue guidance from a prior range of $12.95B - $13.1B to $13.1B - $13.2B for the fiscal year 2026.
When did Vertex Pharmaceuticals (VRTX) last issue guidance?
Vertex Pharmaceuticals (VRTX) last issued guidance on August 3, 2026 for the fiscal year 2026.
